

EVH_MP_2505.MPC Chelation Therapy

Maryland Physicians Care considers the administration of FDA-approved **Chelating Agents** medically necessary for *any* the following indications:

- Primary hemochromatosis when phlebotomy is not possible and the member exhibits at least **ONE** of the following criteria:
 - Inaccessible veins or needle phobia
 - Concomitant anemia
 - Cardiac iron overload that is life-threatening
- Secondary hemochromatosis due to chronic iron overload. Examples include, but are not limited to ⁽¹⁾:
 - Iron overloading anemias (e.g., Thalassemias, sideroblastic anemia)
 - Parenteral iron overload (e.g., red blood cell transfusions, long-term hemodialysis)
 - Chronic liver disease (e.g. Porphyria cutanea tarda, Hepatitis B or C, alcoholic liver disease)
 - Dysmetabolic iron overload syndrome
 - Other, miscellaneous iron overloading conditions (e.g. neonatal iron overload, congenital atransferrinemia)
- Heavy metal toxicity, which includes the following:
 - Arsenic, mercury, iron, copper or gold poisoning when long-term exposure and toxicity has been confirmed through lab results (i.e., blood, plasma, and/or urine results) or clinical findings (i.e., symptoms consistent with metal toxicity) ^(2,3)
 - Aluminum overload in chronic hemodialysis members ^(4,5)
 - Copper overload in members with Wilson's Disease ^(6,7)
 - Lead overload in cases of acute or long-term lead exposure ⁽²⁾

Note: For metals not listed above, additional documentation must be maintained in the medical record.

- Covered Place of Service: Chelation therapy is covered only in the following places of service that can provide the level of care and monitoring required for the procedure:
 - Hospital
 - Hospital-based ambulatory setting

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

- Outpatient hospital
- Emergency room
- Renal dialysis facilities
- Skilled nursing facilities

Limitations

- Chelation therapy is contraindicated in pregnancy ⁽⁸⁾
- Chelation therapy is considered investigational and not medically necessary for the treatment of any of the following:
 - Alzheimer's disease
 - Autism Spectrum Disorder
 - Atherosclerosis
 - Cadmium exposure
 - Cancer
 - Cardiovascular disease - prevention and treatment
 - Chemical Endarterectomy with Edetate Disodium
 - Parkinson's disease
 - Peripheral vascular disease
 - Rheumatoid arthritis
- Non-Covered Locations: Chelation therapy requires close monitoring and is not covered in the following locations that cannot provide the level of care and monitoring required:
 - Office setting
 - Home setting
 - Certain ambulatory surgical centers

Note: Certain oral iron chelation agents may be taken in the home setting

Codes

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
J0470	Injection, dimercaprol, per 100 mg
J0600	Injection, edetate calcium disodium, up to 1,000 mg
J0895	Injection, deferoxamine mesylate, 500 mg
Non-Covered Codes	
J3520	Edetate disodium, per 150 mg
M0300	IV chelation therapy (chemical endarterectomy)

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
ICD-10 codes covered if selection criteria are met:	
D56.1	Beta thalassemia
D56.2	Delta-beta thalassemia
D56.3	Thalassemia minor
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]
D56.5	Hemoglobin E-beta thalassemia
D56.8	Other thalassemias
D56.9	Thalassemia, unspecified
D57.41	Sickle-cell thalassemia, unspecified, with crisis
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration
D57.419	Sickle-cell thalassemia, unspecified, with crisis
D57.00	Hb-SS disease with crisis, unspecified
D57.01	Hb-SS disease with acute chest syndrome
D57.02	Hb-SS disease with splenic sequestration
D57.1	Sickle-cell disease without crisis
D57.20	Sickle-cell/Hb-C disease without crisis
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome
D57.212	Sickle-cell/Hb-C disease with splenic sequestration
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified
D57.3	Sickle-cell trait
D57.80	Other sickle-cell disorders without crisis
D57.811	Other sickle-cell disorders with acute chest syndrome
D57.812	Other sickle-cell disorders with splenic sequestration
D57.819	Other sickle-cell disorders with crisis, unspecified
D64.0	Hereditary sideroblastic anemia
D64.1	Secondary sideroblastic anemia due to disease
D64.2	Secondary sideroblastic anemia due to drugs and toxins
D64.3	Other sideroblastic anemias

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

E83.10	Disorder of iron metabolism, unspecified
E83.110	Hereditary Hemochromatosis
E83.111	Hemochromatosis due to repeated red blood cell transfusions
E83.118	Other Hemochromatosis
E83.119	Hemochromatosis, unspecified
E83.00	Disorder of copper metabolism, unspecified
E83.01	Wilson's disease
E83.09	Other disorders of copper metabolism
E83.52	Hypercalcemia
T37.8X1A	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), initial encounter
T37.8X1D	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), subsequent encounter
T37.8X1S	Poisoning by other specified systemic anti-infectives and antiparasitics, accidental (unintentional), sequela
T37.8X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter
T37.8X2D	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, subsequent encounter
T37.8X2S	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, sequela
T37.8X3A	Poisoning by other specified systemic anti-infectives and antiparasitics, assault, initial encounter
T37.8X3D	Poisoning by other specified systemic anti-infectives and antiparasitics, assault, subsequent encounter
T37.8X3S	Poisoning by other specified systemic anti-infectives and antiparasitics, assault, sequela
T37.8X4A	Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, initial encounter
T37.8X4D	Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined, subsequent encounter
T37.8X4S	Poisoning by other specified systemic anti-infectives and antiparasitics, undetermined sequela
T37.8X5A	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

T37.8X5D	Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter
T37.8X5S	Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela
T45.4X1A	Poisoning by iron and its compounds, accidental (unintentional), initial encounter
T45.4X1D	Poisoning by iron and its compounds, accidental (unintentional), subsequent encounter
T45.4X1S	Poisoning by iron and its compounds, accidental (unintentional), sequela
T45.4X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter
T45.4X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter
T45.4X2S	Poisoning by iron and its compounds, intentional self-harm, sequela
T45.4X3A	Poisoning by iron and its compounds, assault, initial encounter
T45.4X3D	Poisoning by iron and its compounds, assault, subsequent encounter
T45.4X3S	Poisoning by iron and its compounds, assault, sequela
T45.4X4A	Poisoning by iron and its compounds, undetermined, initial encounter
T45.4X4D	Poisoning by iron and its compounds, undetermined, subsequent encounter
T45.4X4S	Poisoning by iron and its compounds, undetermined, sequela
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.4X5D	Adverse effect of iron and its compounds, subsequent encounter
T45.4X5S	Adverse effect of iron and its compounds, sequela
T56.0X1A	Toxic effect of lead and its compounds, accidental (unintentional), initial encounter
T56.0X1D	Toxic effect of lead and its compounds, accidental (unintentional), subsequent encounter
T56.0X1S	Toxic effect of lead and its compounds, accidental (unintentional), sequela
T56.0X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter
T56.0X2D	Toxic effect of lead and its compounds, intentional self-harm, subsequent encounter
T56.0X2S	Toxic effect of lead and its compounds, intentional self-harm,

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

	sequela
T56.0X3A	Toxic effect of lead and its compounds, assault, initial encounter
T56.0X3D	Toxic effect of lead and its compounds, assault, subsequent encounter
T56.0X3S	Toxic effect of lead and its compounds, assault, sequela
T56.0X4A	Toxic effect of lead and its compounds, undetermined, initial encounter
T56.0X4D	Toxic effect of lead and its compounds, undetermined, subsequent encounter
T56.0X4S	Toxic effect of lead and its compounds, undetermined, sequela
T56.1X1A	Toxic effect of mercury and its compound, accidental (unintentional), initial encounter
T56.1X1D	Toxic effect of mercury and its compound, accidental (unintentional), subsequent encounter
T56.1X1S	Toxic effect of mercury and its compound, accidental (unintentional), sequela
T56.1X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter
T56.1X2D	Toxic effect of mercury and its compounds, intentional self-harm, subsequent encounter
T56.1X2S	Toxic effect of mercury and its compounds, intentional self-harm, sequela
T56.1X3A	Toxic effect of mercury and its compounds, assault, initial encounter
T56.1X3D	Toxic effect of mercury and its compounds, assault, subsequent encounter
T56.1X3S	Toxic effect of mercury and its compounds, assault, sequela
T56.1X4A	Toxic effect of mercury and its compounds, undetermined, initial encounter
T56.1X4D	Toxic effect of mercury and its compounds, undetermined, subsequent encounter
T56.1X4S	Toxic effect of mercury and its compounds, undetermined, sequela
T56.4X1A	Toxic effect of copper and its compounds, accidental (unintentional), initial encounter
T56.4X1D	Toxic effect of copper and its compounds, accidental (unintentional), subsequent encounter
T56.4X1S	Toxic effect of copper and its compounds, accidental, (unintentional), initial sequela

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

T56.4X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter
T56.4X2D	Toxic effect of copper and its compounds, intentional self-harm, subsequent encounter
T56.4X2S	Toxic effect of copper and its compounds, intentional self-harm, sequela
T56.4X3A	Toxic effect of copper and its compounds, assault, initial encounter
T56.4X3D	Toxic effect of copper and its compounds, assault, subsequent encounter
T56.4X3S	Toxic effect of copper and its compounds, assault, sequela
T56.4X4A	Toxic effect of copper and its compounds, undetermined, initial encounter
T56.4X4D	Toxic effect of copper and its compounds, undetermined, subsequent encounter
T56.4X4S	Toxic effect of copper and its compounds, undetermined, sequela
T56.891A	Toxic effect of other metals, accidental (unintentional), initial encounter
T56.891D	Toxic effect of other metals, accidental (unintentional), subsequent encounter
T56.891S	Toxic effect of other metals, accidental (unintentional), sequela
T56.892A	Toxic effect of other metals, intentional self-harm, initial encounter
T56.892D	Toxic effect of other metals, intentional self-harm, subsequent encounter
T56.892S	Toxic effect of other metals, intentional self-harm, sequela
T56.893A	Toxic effect of other metals, assault, initial encounter
T56.893D	Toxic effect of other metals, assault, subsequent encounter
T56.893S	Toxic effect of other metals, assault, sequela
T56.894A	Toxic effect of other metals, undetermined, initial encounter
T56.894D	Toxic effect of other metals, undetermined, subsequent encounter
T56.894S	Toxic effect of other metals, undetermined, sequela
T56.91XA	Toxic effect of unspecified metal, accidental (unintentional), initial encounter
T56.91XD	Toxic effect of unspecified metal, accidental (unintentional), subsequent encounter
T56.91XS	Toxic effect of unspecified metal, accidental (unintentional), sequela
T56.92XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter
T56.92XD	Toxic effect of unspecified metal, intentional self-harm, subsequent encounter
T56.92XS	Toxic effect of unspecified metal, intentional self-harm, sequela

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

T56.93XA	Toxic effect of unspecified metal, assault, initial encounter
T56.93XD	Toxic effect of unspecified metal, assault, subsequent encounter
T56.93XS	Toxic effect of unspecified metal, assault, sequela
T56.94XA	Toxic effect of unspecified metal, undetermined, initial encounter
T56.94XD	Toxic effect of unspecified metal, undetermined, subsequent encounter
T56.94XS	Toxic effect of unspecified metal, undetermined, sequela

Policy History

Date	Summary
February 19, 2026	<ul style="list-style-type: none">• This guideline was renumbered from MP.019.MPC Chelation Therapy• Annual Review - Formatting updates throughout the policy; added indications for primary hemochromatosis; removed emergency treatment of hypercalcemia as an indications; other minor updates to Indications; updated Limitations to include pregnancy as a contraindication and some other minor updates; updated description of procedure codes J0470, J0600, J0895, M0300 and S9355; updated description of ICD-10 Codes E83.09, D57.41, D57.411, D57.412, D57.419, D57.00, D57.219, D57.80, D57.819, T56.0X2S, T56.0X4D, T56.1X1A, T56.1X1D, T56.1X1S, T56.1X4S, T56.4X1A, T56.4X1D, T56.4X1S, T56.4X4S with additional formatting updates throughout ICD-10 Codes list; ordered ICD-10 codes to be in numerical order; added Policy History Log; replaced outdated References with updated References

References

1. Bacon BR, Adams PC, Kowdley K V., Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. *Hepatology*. 2011;54(1):328-343. doi:10.1002/hep.24330
2. National Organization for Rare Disorders. Heavy Metal Poisoning.; 2024. <https://rarediseases.org/rare-diseases/heavy-metal-poisoning/>
3. U.S. Department of Health and Human Services. Dimercaprol. US Department of Health and Human Services. Published online January 20, 2026. <https://remm.hhs.gov/dimercaprol.htm>

EVH_MP_2505.MPC Chelation Therapy

Policy Number: EVH_MP_2505.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

4. Rahimzadeh MR, Rahimzadeh MR, Kazemi S, Amiri RJ, Pirzadeh M, Moghadamnia AA. Aluminum Poisoning with Emphasis on Its Mechanism and Treatment of Intoxication. *Emerg Med Int*. Published online January 11, 2022:1-13. doi:10.1155/2022/1480553
5. Jackson J, Preeti R. Aluminum Toxicity. *StatPearls*. Published online October 26, 2024.
<https://www.ncbi.nlm.nih.gov/books/NBK609094/>
6. Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. *Hepatol Commun*. 2023;7(6):e0150. doi:10.1097/HC9.000000000000150
7. National Organization for Rare Disorders. *Wilson Disease.*; 2025.
<https://rarediseases.org/rare-diseases/wilson-disease/>
8. Zoller H, Schaefer B, Vanclooster A, et al. EASL Clinical Practice Guidelines on haemochromatosis. *J Hepatol*. 2022;77(2):479-502. doi:10.1016/j.jhep.2022.03.033

Disclaimer

Maryland Physicians Care medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Maryland Physicians Care and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Maryland Physicians Care reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Maryland Physicians Care. Any sale, copying, or dissemination of said policies is prohibited.